Anna K Jansson
Papers
1
Total Citations
19
H-Index
1
About
Anna K. Jansson is a leading oncological surgeon whose work is transforming the management of testicular cancer, particularly seminoma. Her primary research focus is on reducing the long-term toxicity of standard treatments by pioneering surgical alternatives. Her landmark contribution, drawn from the Swedish Norwegian Testicular Cancer Group, demonstrates that primary retroperitoneal lymph node dissection (RPLND) is a safe and effective treatment for low-volume metastatic seminoma, offering a way to avoid the lifelong morbidity associated with chemotherapy or radiation. This population-based study (2024, 19 citations) provides critical, real-world evidence for a paradigm shift in clinical practice. Dr. Jansson’s work is notable for its direct impact on patient quality of life, addressing the urgent need to de-escalate therapy without compromising oncological outcomes. By championing surgery as a frontline strategy, she is redefining standards of care and offering a compelling, less toxic path for young men facing this diagnosis.
Research Focus
Key Achievements
Top Papers
- 1